Philip Morris International (PM) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is skewed to beat on EPS — consensus sits at the low end of guidance and PM has a 4.9% trailing four-quarter average surprise — but the single biggest swing factor is whether ZYN U.S. shipment volumes show a credible recovery trajectory after Q1's inventory-driven trough.

Heading into Q2 2026, the bar for PM is manageable: consensus EPS of ~$2.04 sits at the midpoint of the company's own Q2 guidance range of $2.02–$2.07 (updated at the June 2 Deutsche Bank conference to reflect an unfavorable $0.03 currency impact from Russian ruble deferred tax effects), and the organic growth algorithm — mid-single-digit revenue growth, solid operating income progression — was reaffirmed in full at that same event. International smoke-free remains the engine, with IQOS adjusted IMS growing ~11% in Q1 and management expressing confidence that Japan's post-excise pantry-loading reversal is tracking in line with expectations; Q2 HTU shipment guidance of 40–42 billion units implies a modest sequential step-down that the Street has already modeled. The estimate trajectory is benign — Q2 EPS consensus has barely moved since the April 22 print ($2.06 as of post-earnings vs. $2.04 today), suggesting no meaningful revision risk in either direction. The stock has rallied ~15% since Q1 earnings, outperforming MO (+12%), XLP (+2%), and SPY (+5%), which means some beat is already priced in at ~23x forward earnings. The key wildcard is ZYN U.S. shipment volume: Q2's underlying base is ~180 million cans (vs. 155 million shipped in Q1), and with ZYN Ultra now shipping in 9mg/11mg moist variants and the FDA's May 2026 enforcement guidance clearing the path for legal products, any sign of accelerating offtake or share stabilization could be the catalyst that re-rates the stock toward the high end of analyst price targets.

• Bar: Consensus EPS of $2.04 sits at the midpoint of PM's own Q2 guidance range ($2.02–$2.07), making it a moderate bar. Revenue consensus of ~$10.6B implies ~4–5% YoY growth, consistent with the mid-single-digit organic growth guide.
• Guidance/Tone: Management tone at the June 2 Deutsche Bank conference was confident — CEO Olczak stated "the whole underlying view for the year remains intact" and reiterated full-year organic guidance. The only change was a currency-driven EPS revision (adjusted FY EPS lowered to $8.31–$8.46 from $8.36–$8.51) and a $500M non-cash RBH impairment charge flagged for Q2.
• Estimate Trajectory: Q2 EPS estimates have drifted slightly lower since the April 22 print ($2.06 post-earnings baseline vs. $2.04 current), tracking the currency revision. FY 2026 EPS consensus of $8.38 sits just above the updated guidance midpoint of $8.39, suggesting estimates are well-anchored to guidance with minimal divergence.
• Stock Setup: PM has rallied ~15% since Q1 earnings to ~$188, outperforming all benchmarks. At ~23x forward P/E, the stock is pricing in continued execution but not a step-change acceleration. The multiple is below the mid-2025 peak, leaving room for re-rating if ZYN U.S. inflects.
• Wildcard: ZYN U.S. offtake and shipment trajectory. Q1 offtake grew only ~10% (Nielsen) with shipments declining to 155M cans due to inventory normalization. Q2 shipments should track offtake against a ~180M can underlying base. Any sign of acceleration above 10% offtake growth — driven by ZYN Ultra launch and FDA enforcement tailwinds — would be a meaningful positive surprise.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a moderate bar — EPS sits at the midpoint of guidance and revenue estimates imply a step-up from Q1's organic growth. ZYN U.S. can volume is the bigger swing factor: the Q2 underlying base of ~180M cans is higher than Q1's 155M shipped, and any shipment shortfall vs. offtake would signal continued inventory headwinds.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data; PM Q1 2026 Earnings Call (April 22, 2026); Deutsche Bank Conference (June 2, 2026). Q2 2025 actuals and Q2 2026 consensus from Visible Alpha. ZYN U.S. underlying base of ~180M cans per Q1 2026 earnings call guidance.

Table 2 — Beat/Miss History (Last 8 Quarters)

Top 2 KPIs: Adjusted Diluted EPS & ZYN U.S. Can Volume (shipments)

Pattern: PM has beaten adjusted EPS consensus in every one of the last 8 quarters, with an average surprise of ~4.9%; the Q1 2026 ZYN U.S. shipment miss was a known inventory normalization event, not a demand signal, and the Street has since reset its ZYN volume models to track offtake rather than shipments. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year organic guidance is unchanged since Q1 earnings — the only post-earnings revision was a currency-driven EPS reduction at the June 2 Deutsche Bank conference, plus a $500M non-cash RBH impairment charge flagged for Q2. Underlying business tone remains confident, with management reiterating the three-year growth algorithm and expressing optimism on ZYN Ultra, IQOS ILUMA U.S. timing, and buyback resumption.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have barely moved since the Q1 print — Q2 EPS consensus drifted down ~$0.02 tracking the currency revision, while FY 2026 EPS consensus of $8.38 sits just above the updated guidance midpoint. The gap between consensus and guidance is minimal, suggesting the Street has fully absorbed the DB conference revision and is not pricing in incremental organic upside or downside.

The small downward drift in EPS estimates (-1.0% for Q2, -0.7% for FY) tracks precisely with the currency revision at the DB conference and does not reflect any organic deterioration. Consensus sitting ~2.3% above the revised Q2 guidance midpoint suggests the Street is giving PM credit for a slight tax rate or FX beat, consistent with the Q1 pattern. Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: PM has rallied +14.7% since Q1 earnings (Apr 22 → Jul 21), sharply outperforming MO (+12.0%), XLP (+2.4%), and SPY (+5.2%) — the move is driven by a combination of multiple expansion (smoke-free transformation re-rating) and positive estimate revisions, with the stock briefly pulling back in early June on the DB conference guidance revision before recovering strongly in mid-July ahead of the Q2 print.

PM vs. MO vs. XLP (Consumer Staples ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings Date (Apr 22, 2026). Source: Stock Price Data (Yahoo Finance).

• Apr 22–23 (Q1 Earnings): PM initially rallied +3.2% the day after earnings on the EPS beat, then gave back gains as investors focused on ZYN U.S. shipment miss and the stock closed the week near flat vs. the earnings-day open.
• May 11–14 (Breakout): PM surged from ~$170 to ~$192, a ~13% move in four sessions, driven by broader market risk-on sentiment and growing conviction in the smoke-free transformation story; this was the primary driver of outperformance vs. XLP and SPY.
• Jun 2 (DB Conference / Guidance Revision): PM pulled back modestly (~-1%) on the day of the DB conference after the EPS guidance revision (currency + RBH impairment), but the stock quickly stabilized as investors recognized the revision was non-organic.
• Jul 9 (CFO Departure Disclosed): PM declined ~3.2% on the day Emmanuel Babeau's departure was disclosed (effective Aug 1, 2026, replaced by Massimo Andolina), reflecting short-term uncertainty around leadership transition ahead of earnings.
• Jul 16–17 (Pre-Earnings Rally): PM surged from ~$181 to ~$193 in two sessions, suggesting institutional positioning ahead of the Q2 print and/or positive read-throughs from Altria's Q2 results (reported Jul 30, 2026 per consensus expectations).

6. Peer Commentaries — Read-Through for PM Q2 2026

Key Takeaway: Two peers provided material Q2 2026 read-throughs: BAT's June 2 pre-close call is the most directly relevant, confirming accelerating nicotine pouch category growth, FDA enforcement tailwinds, and a competitive ZYN challenge from Velo Plus — all of which frame the context for PM's ZYN U.S. trajectory. Altria's Q1 2026 earnings (April 30) provide the most recent read on U.S. oral nicotine category dynamics, confirming 9.5% industry volume growth and on! PLUS national rollout momentum, which is relevant context for ZYN's competitive environment heading into Q2.

Peer 1: British American Tobacco (BAT) — Q2 2026 Pre-Close Conference Call (June 2, 2026)

Relevance: BAT's Velo Plus is ZYN's primary U.S. competitor in nicotine pouches. BAT's pre-close call covered H1 2026 performance and provided direct commentary on the U.S. oral nicotine category, FDA regulatory environment, and competitive dynamics — all directly read-through to PM's ZYN business.

• U.S. Nicotine Pouch Category Growth Accelerating: BAT confirmed it is "the fastest-growing company in total nicotine" and expects "strong double-digit revenue growth" in modern oral for the full year. Velo Plus gained 10.4 percentage points of total volume share year-to-date to reach 28.4%, capturing "100% of category value growth year-to-date." Read-through for PM: Category growth is robust, which is a positive backdrop for ZYN. However, Velo Plus's rapid share gains (from ~18% to 28.4%) are coming directly at ZYN's expense, confirming the competitive pressure PM acknowledged on its Q1 call.
• ZYN Price Premium Under Pressure: BAT disclosed that Velo Plus started at a price index of 65% vs. the leading brand (ZYN) and has now moved to 90–95% of ZYN's price. The gap between Velo Plus's volume share (28.4%) and value share (23.1%) has narrowed significantly. Read-through for PM: This confirms PM CEO Olczak's June 2 comment that ZYN is retailing at a ~160–170 price index (60–70% premium) and that "adjusting the price premium is needed." ZYN Ultra's lower list price-per-pouch is the right strategic response, but the competitive pricing dynamic is real and ongoing.
• FDA Enforcement Guidance: Net Positive for Legal Players: BAT "welcomed the FDA's recently published prioritization guidance as an important step toward effective enforcement and expanding market access for responsible industry players." BAT noted that states with comprehensive enforcement tools have seen "a decline in the illegal market and a return to growth for legal markets." BAT is "confident in the strength of our science and portfolio" and sees "a clear pathway to marketing authorisations for our leading higher moisture products" through the PMTA pilot. Read-through for PM: Directly corroborates PM's view that FDA enforcement is a net positive for ZYN. Both companies are participating in the PMTA pilot program, and both see the enforcement guidance as reducing the oxygen available for illicit market participants.
• U.S. Vapor Recovery: BAT confirmed Vuse gained 4.2 percentage points of U.S. value share year-to-date to reach 56%, with U.S. vapor now expected to deliver "double-digit revenue growth in H1 and full year." BAT plans to introduce flavored vapor in Q3 2026 via supplemental PMTAs. Read-through for PM: Positive for the broader smoke-free category. PM's VEEV is a smaller player in U.S. vapor, but the category recovery driven by enforcement and legal market expansion is a tailwind for all authorized products.
• Japan Heated Tobacco: Inventory Headwinds Persist: BAT flagged that heated tobacco revenue is expected to be "down low double digits" in H1 and full year, with the "major driver" being "adjustment in stocks in the main distributor in Japan" that "will carry on throughout the year." Glo's gross volume share was down 1.6 percentage points in top markets. Read-through for PM: Confirms that Japan's post-excise dynamics are creating industry-wide headwinds, not just IQOS-specific issues. However, IQOS's dominant share position (~53% of Japan HTB category) means it is better insulated than Glo. PM's Q2 HTU guidance of 40–42B units already reflects the Japan pantry-loading reversal.
• U.S. Nicotine Pouch Consumption Runway: BAT CEO noted that average daily consumption in the U.S. is currently 3.6 pouches per day vs. 6–8 in Europe and 12 in Sweden, suggesting significant long-term category growth potential. BAT expects industry revenue to "almost triple by 2030." Read-through for PM: Validates PM's long-term ZYN thesis. The category is still in early innings, and both companies are investing heavily to expand the consumer base rather than just compete for existing users.

Peer 2: Altria Group (MO) — Q1 2026 Earnings Call (April 30, 2026)

Relevance: Altria's Q1 2026 earnings (reported April 30, 2026, after PM's Q1 print) provided the most recent read on U.S. oral nicotine category dynamics, FDA regulatory developments, and consumer macro conditions. Altria's on! PLUS is a direct ZYN competitor, and its commentary on category growth, pricing, and FDA pilot program progress is directly relevant to PM's Q2 ZYN outlook.

• U.S. Oral Nicotine Category Growing ~9.5%: Altria reported that total oral tobacco industry volume rose 9.5% over the past six months, driven by nicotine pouches, which now represent more than 58% of total oral tobacco. The nicotine pouch category grew 9.1 share points in Q1. Read-through for PM: Category growth is healthy but has moderated from prior elevated rates (PM CEO noted category growing "somewhere in the range of 20–30%" at the DB conference, suggesting the 9.5% figure may reflect a different measurement window). The category is still growing, which is the key point.
• on! PLUS National Rollout: Competitive Pressure on ZYN: Altria began shipping on! PLUS nationwide in March 2026, achieving shelf presence in ~100,000 stores (85% of nicotine pouch category volume) by end of Q1. on! PLUS is "the first and only product authorized under the FDA's pilot program." on! and on! PLUS together held 7.8% of total oral tobacco category share (down 0.8 pp YoY but up 0.2 pp sequentially). Read-through for PM: on! PLUS's national rollout adds another authorized competitor to ZYN, but its 7.8% share is still far below ZYN's dominant position. The FDA pilot program authorization for on! PLUS is the same mechanism PM is using for ZYN Ultra, validating the regulatory pathway.
• FDA Enforcement: Illicit Vapor Still ~70% of Market: Altria management described current e-vapor conditions as "still, call it, approximately 70% of the volume is illicit flavor disposables," indicating ongoing regulatory and compliance challenges. However, federal and state enforcement intensified in Q1, contributing to moderation in cross-category movement between cigarettes and vapor. Read-through for PM: Consistent with PM's view that the vape illicit market is resolvable through faster FDA authorizations. The enforcement progress is a positive for VEEV and for the broader smoke-free category.
• Consumer Macro Pressure: Discount Segment Growing: Altria flagged "moderated labor industry growth on combustible and e-vapor product volumes and increased macroeconomic uncertainty facing adult nicotine consumers." The discount cigarette segment is gaining share, with Basic capturing nearly all year-over-year discount segment share gains. Read-through for PM: PM's combustibles are primarily international, so U.S. consumer macro pressure is less directly relevant. However, the macro headwind on U.S. consumer spending could weigh on ZYN's premium pricing strategy and validate PM's decision to reduce ZYN's price premium via ZYN Ultra.
• Oral Tobacco Margins: 67.4%, Down 1.8 pp: Altria's oral tobacco products segment adjusted OCI margin was 67.4% in Q1, down 1.8 pp YoY due to higher marketing spend and product mix shift toward pouches. Shipment volume for nicotine pouches increased 17.6%. Read-through for PM: PM has consistently stated ZYN maintains best-in-class margins above IQOS average. Altria's margin compression from pouch investment is a reminder that the competitive environment requires ongoing investment, which PM is also making (ZYN Ultra launch, Ferrari F1 partnership).
• FY 2026 EPS Guidance Reaffirmed: $5.56–$5.72: Altria reaffirmed full-year adjusted diluted EPS guidance of $5.56–$5.72 (+2.5% to +5.5% YoY), with growth now expected to be more balanced between H1 and H2 given the strong Q1. Read-through for PM: Altria's guidance reaffirmation is a positive signal for the broader tobacco sector's earnings stability, though PM's growth algorithm (+7.5% to +9.5% currency-neutral EPS growth) is significantly more robust given its smoke-free transformation.

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the ZYN Ultra launch in June 2026 (9mg/11mg moist variants), which directly addresses the portfolio gap that has been driving ZYN's share losses — its success in Q2 is the single most important variable for the print and the stock's reaction.

• Jun 2026 — ZYN Ultra Shipments Commence (9mg & 11mg Moist Variants): PM began shipping ZYN Ultra in a 20-pouch can format at a lower list price-per-pouch than the flagship dry ZYN portfolio, directly addressing the portfolio asymmetry vs. Velo Plus and on! PLUS. CEO Olczak confirmed at the DB conference that shipments started "this week" (June 2). Implication: ZYN Ultra is the key catalyst for H2 ZYN recovery. Q2 will capture only a partial quarter of ZYN Ultra shipments, but the launch trajectory and initial offtake data will be closely watched.
• Jun 2, 2026 — Deutsche Bank Conference: FY EPS Guidance Revised for Currency & RBH Impairment: PM updated FY 2026 adjusted diluted EPS guidance to $8.31–$8.46 (from $8.36–$8.51) and Q2 EPS guidance to $1.97–$2.02 (from $2.02–$2.07), reflecting: (1) unfavorable currency shift from Russian ruble deferred tax liabilities, and (2) a ~$500M non-cash impairment of RBH (Canadian affiliate), representing $0.33/share. All organic assumptions unchanged. Implication: The revision was non-organic and well-explained; the stock's modest pullback on the day was quickly reversed. The RBH impairment will be a Q2 reported EPS headwind but is excluded from adjusted EPS.
• May 2026 — FDA Enforcement Priorities Guidance for Nicotine Pouches: FDA published enforcement priorities guidance for unauthorized nicotine pouch products with pending applications, creating a clearer pathway for legal products like ZYN Ultra. PM management framed this as "a net positive" and "a convergence of FDA and PMI views on how the market should evolve." Implication: Reduces the oxygen available for illicit market participants and validates PM's PMTA pilot program strategy. Directly enabled the ZYN Ultra launch.
• Jul 9, 2026 — CFO Emmanuel Babeau Departure Disclosed (Effective Aug 1, 2026): PM filed an 8-K disclosing that CFO Emmanuel Babeau will be replaced by Massimo Andolina (current President, Europe Region) effective August 1, 2026. Babeau will remain as Strategic Advisor to CEO Olczak through March 31, 2027. Separation terms include continued base salary (CHF 1,260,012), 2026 annual incentive eligibility, and RSU portion of 2027 equity award. Implication: Leadership transition creates short-term uncertainty, particularly as Andolina will be presenting his first earnings call as CFO on July 22. The stock declined ~3.2% on the disclosure. Andolina's European background is relevant given PM's international smoke-free growth engine.
• Jun 29, 2026 — PM Prepays €1 Billion of Term Loan Facility: PM filed an 8-K confirming prepayment of €1 billion of its term loan facility, accelerating deleveraging toward the 2x net debt/EBITDA target. Implication: Positive signal on balance sheet trajectory and buyback resumption timeline. Management has indicated that conversations about excess cash deployment are "in front of us" once the leverage target is reached.
• Apr 29, 2026 — PM Completes $1.5 Billion Debt Offering: PM issued $1.5 billion in notes, extending its debt maturity profile. Implication: Routine capital markets activity; no material impact on near-term earnings.
• Apr 22, 2026 — FDA Reauthorizes Previous IQOS Version as Modified Risk Tobacco Product: FDA reauthorized the previous version of IQOS as a Modified Risk Tobacco Product, maintaining PM's regulatory differentiation in the U.S. market. Management expressed confidence that IQOS ILUMA U.S. authorization is "very close." Implication: Positive regulatory signal. IQOS ILUMA U.S. launch remains a significant unpriced catalyst; any update on the timeline at Q2 earnings would be a meaningful positive.
• May 2026 — ZYN by IQOS Expanding in Tokyo: PM launched ZYN by IQOS in Tokyo through IQOS stores and convenience retailers, leveraging a decade of IQOS brand investment to accelerate pouch adoption in Japan. Implication: Demonstrates the multi-category infrastructure leverage thesis in action. Japan is a large and growing oral nicotine market.
• EU Tobacco Excise Directive: Outcome Expected by End of Q2 2026: Management flagged at the DB conference that EU tobacco excise directive negotiations are in final stages, with an outcome expected "within weeks" (by end of Q2 2026). Management expressed cautious optimism. Implication: A favorable outcome (differential taxation favoring smoke-free products) would be a significant positive for PM's European business. Management may provide an update at Q2 earnings.
• Apr 2026 — France Bans Nicotine Pouches: France implemented a ban on nicotine pouches in April 2026, criminalizing sale, possession, and use with penalties of up to five years in prison. PM management characterized it as "irrational regulation" and a "temporary setback." Implication: Modest negative for PM's European smoke-free revenue, but France is a relatively small nicotine pouch market. Management expressed confidence that "sensible regulation will ultimately prevail."

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by executives or directors since Q1 earnings. The only Form 4 activity in the period was routine director compensation grants (transaction code A) at the May 6, 2026 Annual Shareholder Meeting — no insider signal to read into heading into Q2 earnings.

All nine transactions are routine director equity grants (Form 4 transaction code A = Award/Grant) at the May 6, 2026 Annual Shareholder Meeting. These are not open-market purchases or sales and carry no informational signal about management's view of the stock. No open-market buys (code P) or sells (code S) were filed by any PM insider since Q1 earnings. Source: SEC Form 4 Filings Database.